ProCE Banner Activity

Experts Discuss Key Topics in Treating Hepatobiliary Cancers

Clinical Thought

In this commentary, 3 experts discuss contemporary issues in managing patients with advanced and early hepatocellular carcinoma and biliary tract cancers, with a focus on use of novel immunotherapy combinations. 

Released: July 11, 2023

Expiration: July 10, 2024

Share

Faculty

Thomas A. Abrams

Thomas A. Abrams, MD

Institute Physician
Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Mitesh J. Borad

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Stacey Stein

Stacey Stein, MD

Associate Professor of Medicine
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational from AstraZeneca.

AstraZeneca

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Thomas A. Abrams, MD

Institute Physician
Director, Liver Tumor Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Thomas A. Abrams, MD: consultant/advisor/speaker: AstraZeneca, Exelixis, Servier; researcher: Eisai.

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Mitesh J. Borad, MD: consultant: Merck; research support (to institution): AstraZeneca, Incyte, Taiho.

Stacey Stein, MD

Associate Professor of Medicine
Department of Medical Oncology
Yale University
Medical Oncologist
GI Oncology
Yale Cancer Center
New Haven, Connecticut

Stacey Stein, MD: consultant/advisor/speaker: AstraZeneca, Eisai, Exelixis, Genentech, Imvax, Ipsen, Merck, QED.